Alchemia Limited, (ASX – ACL) (Alchemia or the Company), an Australian drug discovery and development company, announces today its results for the financial year 2013. In the year, the Company saw significant progress across its key assets...
Avita Medical ASX announcement link here.
Read more about Avita Medical Appendix 4E Year Ending 30 June 2013
Pharmaceutical company Pharmaxis (ASX:PXS) today announced it will scale back resources and investments dedicated to the launch of Bronchitol in France due to delays in reaching an agreement with French authorities on a reimbursed price for the cystic fibrosis treatment.
Read more about Pharmaxis Announces Delay to French Pricing for Bronchitol
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (“Biota” or the “Company”), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, including the resignation of Dr. Jeffrey Errington, and the appointment of Mr. John P. Richard to fill the vacancy created by Dr. Errington’s resignation.
AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the treatment ofPseudomonas aeruginosa (P. aeruginosa) at the 20th Biennial Evergreen International Phage Meeting held inOlympia, Washington, USA. P. aeruginosa is the major cause of lung infections in cystic fibrosis (CF) patients.
The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF).
Alchemia ASX announcements.
Avita Medical press release link here.